CN100518726C - 莫达非尼化合物的药用溶液 - Google Patents

莫达非尼化合物的药用溶液 Download PDF

Info

Publication number
CN100518726C
CN100518726C CNB018171273A CN01817127A CN100518726C CN 100518726 C CN100518726 C CN 100518726C CN B018171273 A CNB018171273 A CN B018171273A CN 01817127 A CN01817127 A CN 01817127A CN 100518726 C CN100518726 C CN 100518726C
Authority
CN
China
Prior art keywords
compositions
modafinil
peg
compounds
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018171273A
Other languages
English (en)
Chinese (zh)
Other versions
CN1468096A (zh
Inventor
马丁·J·雅各布斯
布拉德利·T·麦金太尔
皮于诗·R·帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CN1468096A publication Critical patent/CN1468096A/zh
Application granted granted Critical
Publication of CN100518726C publication Critical patent/CN100518726C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB018171273A 2000-10-11 2001-10-11 莫达非尼化合物的药用溶液 Expired - Fee Related CN100518726C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23948800P 2000-10-11 2000-10-11
US60/239,488 2000-10-11
US09/974,473 2001-10-10
US09/974,473 US6489363B2 (en) 2000-10-11 2001-10-10 Pharmaceutical solutions of modafinil compounds

Publications (2)

Publication Number Publication Date
CN1468096A CN1468096A (zh) 2004-01-14
CN100518726C true CN100518726C (zh) 2009-07-29

Family

ID=26932612

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018171273A Expired - Fee Related CN100518726C (zh) 2000-10-11 2001-10-11 莫达非尼化合物的药用溶液

Country Status (21)

Country Link
US (1) US6489363B2 (cg-RX-API-DMAC7.html)
EP (1) EP1324755B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004510816A (cg-RX-API-DMAC7.html)
KR (1) KR100846914B1 (cg-RX-API-DMAC7.html)
CN (1) CN100518726C (cg-RX-API-DMAC7.html)
AT (1) ATE478662T1 (cg-RX-API-DMAC7.html)
AU (2) AU9678501A (cg-RX-API-DMAC7.html)
BG (1) BG66221B1 (cg-RX-API-DMAC7.html)
BR (1) BR0114813A (cg-RX-API-DMAC7.html)
CA (1) CA2425218C (cg-RX-API-DMAC7.html)
CZ (1) CZ2003966A3 (cg-RX-API-DMAC7.html)
DE (1) DE60142913D1 (cg-RX-API-DMAC7.html)
EA (1) EA005572B1 (cg-RX-API-DMAC7.html)
HU (1) HU229424B1 (cg-RX-API-DMAC7.html)
IL (2) IL155263A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03003150A (cg-RX-API-DMAC7.html)
NO (1) NO333096B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ525166A (cg-RX-API-DMAC7.html)
PL (1) PL214879B1 (cg-RX-API-DMAC7.html)
SK (1) SK287436B6 (cg-RX-API-DMAC7.html)
WO (1) WO2002030413A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
SK287126B6 (sk) * 2000-10-11 2009-12-07 Cephalon, Inc. Kompozície obsahujúce modafinilové zlúčeniny, spôsob ich prípravy a ich použitie
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
CA2519117C (en) * 2003-03-17 2010-03-02 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
BRPI0500520A (pt) * 2005-02-16 2006-09-26 Henry Jun Suzuki uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas
AU2006272874B2 (en) * 2005-07-21 2010-03-11 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
EP2056811B8 (en) * 2006-08-14 2018-03-21 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
CA2629979A1 (en) * 2008-04-25 2009-10-25 Pharmascience Inc. Novel resveratrol compositions
FR2987265B1 (fr) 2012-02-28 2014-02-28 Debregeas Et Associes Pharma Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application
FR2987266B1 (fr) 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
AU2013330993B2 (en) * 2012-10-18 2018-03-01 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180745A (en) * 1990-06-14 1993-01-19 Laboratoire L. Lafon Method for providing a neuroprotective effect
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2771004B1 (fr) 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180745A (en) * 1990-06-14 1993-01-19 Laboratoire L. Lafon Method for providing a neuroprotective effect
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size

Also Published As

Publication number Publication date
CZ2003966A3 (cs) 2003-09-17
US6489363B2 (en) 2002-12-03
ATE478662T1 (de) 2010-09-15
HUP0302478A2 (hu) 2003-11-28
HK1057336A1 (en) 2004-04-02
EP1324755A1 (en) 2003-07-09
NO333096B1 (no) 2013-03-04
PL361134A1 (en) 2004-09-20
BG107720A (bg) 2004-01-30
NO20031648D0 (no) 2003-04-10
CA2425218C (en) 2010-10-05
AU2001296785B2 (en) 2006-03-16
BG66221B1 (bg) 2012-06-29
HU229424B1 (hu) 2013-12-30
EA200300450A1 (ru) 2003-08-28
SK287436B6 (sk) 2010-09-07
MXPA03003150A (es) 2003-07-14
PL214879B1 (pl) 2013-09-30
HUP0302478A3 (en) 2005-05-30
SK4402003A3 (en) 2003-09-11
BR0114813A (pt) 2005-01-25
JP2004510816A (ja) 2004-04-08
KR20030055279A (ko) 2003-07-02
IL155263A0 (en) 2003-11-23
CA2425218A1 (en) 2002-04-18
US20020099097A1 (en) 2002-07-25
KR100846914B1 (ko) 2008-07-17
NZ525166A (en) 2006-10-27
EP1324755B1 (en) 2010-08-25
CN1468096A (zh) 2004-01-14
EA005572B1 (ru) 2005-04-28
NO20031648L (no) 2003-06-04
WO2002030413A1 (en) 2002-04-18
DE60142913D1 (de) 2010-10-07
IL155263A (en) 2007-07-24
AU9678501A (en) 2002-04-22

Similar Documents

Publication Publication Date Title
CN100518726C (zh) 莫达非尼化合物的药用溶液
CN100423717C (zh) 含莫达非尼化合物的药物溶液及其在制备治疗不同疾病的药物中的用途
JP6273589B2 (ja) 安定化されたカリスバメートの小児用懸濁液
AU2001296785A1 (en) Pharmaceutical solutions of modafinil compounds
JP2004517052A (ja) モダフィニル化合物含有組成物
CN100584322C (zh) 包含莫达非尼化合物的组合物
HK1057336B (en) Pharmaceutical solutions of modafinil compounds
HK1079446B (en) Pharmaceutical solid dispersions of modafinil compounds
HK1054688B (en) Compositions comprising modafinil compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090729

Termination date: 20151011

EXPY Termination of patent right or utility model